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Abstract
Background: Sentinel lymph node (SLN) biopsy has been used to assess patients with papillary thyroid carcinoma
(PTC). To achieve its full potential the rate of SLN identification must be as close to 100 percent as possible. In the
present study we compared the combination of preoperative lymphoscintigraphy scanning by sulfur colloid
labeled with 99 m Technetium, gamma-probe guided surgery, and methylene blue with methylene blue, alone, for
sentinel node identification in younger women with unilateral low-risk PTC.
Methods: From January 2004 to January 2007, 90 female patients, ages 23 to 44 (mean = 35), with unilateral low-
risk PTC (T1-2N0M0) were prospectively studied. Mean tumor size was 1.3 cm (range, 0.8-3.7 cm). All patients
underwent unilateral modified neck dissection. Prior to surgery, patients had, by random assignment, identification
and biopsy of SLNs by methylene blue, alone (Group 1), or by sulfur colloid labeled with 99 m Technetium,
gamma-probe guided surgery and methylene blue (Group 2).
Results: In the methylene blue group, SLNs were identified in 39 of 45 patients (86.7%). Of the 39 patients, 28
(71.8%) had positive cervical lymph nodes (pN+), and 21 patients (53.8%) had pSLN+. In 7 of the 28 pN+ patients
(25%), metastases were also detected in non-SLN, thus giving a false-negative rate (FNR of 38.9% (7/18), a negative
predictive value (NPV) of 61.1% (11/18), and an accuracy of 82.1% (32/39). In the combined technique group, the
identification rate (IR) of SLN was 100% (45/45). Of the 45 patients, 27 (60.0%) had pN+, 24 (53.3%) had pSLN+.
There was a FNR of 14.3% (3/21), a NPV of 85.7% (18/21), and an accuracy of 93.3% (42/45). The combined
techniques group was significantly superior to the methylene blue group in IR (p = 0.035). There were no
significant differences between two groups in sensitivity, specificity, NPV, or accuracy. Location of pN+ (55 patients)
in 84 patients was: level I and V, no patients; level II, 1 patient (1.2%); level III, 6 patients (7.2%); level III and IV, 8
patients (9.5%); level IV, alone, 8 patients (9.5%); level VI, 32 patients (38.1%). In all 90 patients, IR of SLN was 93.3%,
FNR, 25.6%, NPV, 74.4%, and accuracy rate, 88.1 percent.
Conclusions: Compared to a single technique, there was a significantly higher SLN identification rate for the
combined technique in younger female with ipsilateral, low-risk PTC (T1-2N0M0). Thus, a combined SLN biopsy
technique seems to more accurately stage lymph nodes, with better identification of SLN located out of the
central compartment. Regardless of the procedure used, the high FNR renders the current SLN techniques
unsuitable for routine practice. Based on these results, prophylactic node dissection of level VI might be considered
because 38.1% of our patients had such node metastases.
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Nodal metastases are a significant risk factor for survival
in patients with papillary thyroid cancer (PTC) [1].
Recent studies have suggested the use of sentinel lymph
node (SLN) detection as a less invasive method for
studying lymphatic metastatic spread in patients with
breast [2,3], melanoma [4], cervical [5,6], and thyroid
cancers [7,8]. SLN biopsy has potential advantages, for
example, in reducing morbidity compared with elective
lymph node dissection, and could offer a standardized
technique of lymph node evaluation in PTC patients.
Because of its high sensitivity, accuracy and low false-
negative rate in predicting axillary lymph node (ALN)
status, SLN biopsy has obtained widespread consensus
and replaced routine ALN dissection as the standard for
staging in breast cancer [9]. The success of SLN biopsy
in breast cancer has set a good example for other types
of solid tumors [3,4,6], including thyroid cancer [7,8]. It
has been demonstrated that SLN biopsy for thyroid can-
cer is both feasible and safe, using intraoperative isosul-
fan blue vital dye or preoperative lymphoscintigraphy
scanning [7,8]. However, there are differences between
thyroid and breast cancer, so that questions need be
answered before the utility of SLN biopsy becomes stan-
dard practice. For example, while lymphatic drainage is
largely orderly progression in breast cancer, it is not as
predictable in thyroid cancer, perhaps due to prior thyr-
o i dd i s e a s e .T h u s ,i th a sb e en suggested that there be
further investigation [7]. Whether SLN biopsy in thyroid
cancer has a predictive value similar to that in breast
cancer, thus replacing neck dissection, is needs to be
confirmed.
Most studies concerning the SLN biopsy in thyroid
cancer have been conducted in Western populations
[7,8,10-20], while similar data is not available for the
Chinese population. Moreover, the means used to iden-
tify the SLN varies. Some rely on intraoperative of blue
dye (isosulfan blue dye, Canada)[7], patent blue dye
[Patent Blue-V, Hong Kong) [17], methylene blue [Japan
13]), radiotracer (
99 mTc-colloid, Turkey) [21],
99 mTc
sulfur colloid (Switzerland) [19], and
99 mTc nanocolloid
(Italy) [19], to identify sentinel nodes. However, others
rely on blue dye, alone. Furthermore, the risk of nodal
metastases varies considerably between age and tumor
size [22]. Age is the most important prognostic factor
for thyroid cancer. According to the National Thyroid
Cancer Treatment Cooperative Study (NTCTCS) staging
classification registration, patients older than 45 with
cervical lymph node metastases were classified as stage
III (high risk), whereas those younger than 45 with such
lymph node metastases were considered as stage I (low
risk) [22]. The comparative analyses of SLN biopsy by
methylene blue, only, or the combined technique have
not been reported in younger-than-45 female patients
with ipsilateral, low-risk PTC (T1-2N0M0)i ne i t h e rt h e
Western or Chinese populations. Doing so could aid in
determining the use of SLN biopsy in this PTC group.
For the above reasons, we hypothesized that SLN
biopsy could provide accurate assessment of cervical
lymph nodes, as it does in breast cancer, and initiated a
clinical trial to define its role. By using intraoperative
methylene blue, only, or the combined techniques (preo-
perative lymphoscintigraphy scanning by sulfur colloid
labeled with
99 m Technetium, gamma-probe guided sur-
gery, and intraoperative blue dye injection). Further, we
sought to identify which technique might have a better
predictive value.
Methods
Patients
The study was approved by the institutional review
board of Wenzhou Medical College, and informed con-
sent was obtained in writing from all patients after dis-
cussion of risks and benefits with the operating surgeon.
From January 2004 to January 2007, all patients with a
preoperative diagnosis of PTC by fine-needle aspiration,
clinically node-negative detected by clinical examination
and ultrasound were asked to participate in this study.
All were female and had only one unilateral tumor site
by ultrasound. Exclusion criteria were a previous history
of neck operation, current pregnancy, and known hyper-
sensitivity to ethylene blue, age younger than 15 years
or older than 44 years at diagnosis, tumor more than 4
cm in greatest dimension and limited to the thyroid, or
extending beyond the thyroid under ultrasound, or
tumor in isthmus. Preoperative evaluation included his-
tory, complete physical examination, routine laboratory
evaluation, including serum TSH measurement, ultra-
sound of thyroid and neck, including ipsilateral cervical
lymph nodes, and chest x-ray. All patients underwent
attempted SLN biopsy, followed by unilateral modified
radical neck dissection.
SLN Biopsy
All surgeons had performed more than 20 SLN biopsies
prior to the study, and had experience with thyroid SLN
procedures. The day prior to the operation, lymphoscin-
tigraphy was performed only for patients randomized to
t h ec o m b i n e dp r o c e d u r eg r o u p .As i n g l ed o s eo f9 9
mTc sulfur colloid (~0.5 ml) was injected in the primary
tumor for lymphoscintigraphy and intraoperative lymph
node detection. Ten to 15 minutes after injection,
dynamic images were detected by single photon emis-
sion computed tomography (PHILIPS Vertex V60, USA)
to visualize lymphatic drainage. The position of the sen-
tinel node was marked on the skin overlying the “hot
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Page 2 of 7spots” [23]. The operation was performed within 24 h
after lymphoscintigraphy. After induction anesthesia, a
standard transverse cervical incision was made, cuta-
neous flaps developed, and strap muscles retracted later-
ally. The thyroid lobe containing the tumor was
exposed, dividing the medial thyroid vein and the upper
pedicle. Both parathyroid glands were identified.
Approximately 1.0 mL of 1% methylene blue was admi-
nistered into the primary tumor with a 26-gauge needle.
Care was taken not to stain surrounding tissue with
blue dye. The thyroid gland was replaced in its normal
position, and gentle massage was applied for 3 minutes.
A combination of lymphoscintigraphy, blue lymph vessel
and blue node identification, and a hand-held probe
were used for tracing to the SLN. An SLN was defined
a sa n yb l u en o d e ,o ra n yn o d et h a tc o u l db ei d e n t i f i e d
as substantially radioactive above background activity. A
specific SLN-to-background ratio was more than two
for defining an SLN [24]. After the first radioactive SLN
was removed, any node containing radioactive counts ≥
10% of the ex vivo count of the most radioactive SLN
was considered to be an additional SLN. The SLN was
excised and radioactivity measured ex vivo to confirm
nodal activity. After the SLN was removed, a central
lymphadenectomy, unilateral total lobectomy and modi-
fied radical neck dissection were completed. Lymph
nodes, including SLN, were sectioned along the long
axis into two sections and then submitted for routine
hematoxylin-eosin (H-E) staining. Each tissue block was
sectioned serially. Location of positive lymph nodes (pN
+) was recorded according to the Neck Dissection Clas-
sification update (revisions proposed by American Head
and Neck Society and American Academy of Otolaryn-
gology-Head and Neck Surgery [25]).
Statistical Analysis
Results of SLN biopsy were quantified using the follow-
ing definitions: accuracy = (true positive + true nega-
tive)/(total patients); sensitivity = (true positive)/(true
positive + false negative); and specificity = (true nega-
tive)/(true negative + false positive). All data were statis-
tically analyzed using chi-squared test. Fisher’s exact test
was used for comparison, if necessary. All statistical
tests were two-sided and P < 0.05 was considered signif-
icant. All statistical analyses were performed with SPSS
statistical software package 15.0.
Results
Between January 2004 to January 2007, 90 patients were
enrolled and randomly divided into two groups. Mean
age was 35.1 years (range, 23-44 years). Mean tumor
size was 1.3 cm (range, 0.8-3.7 cm). Fifty-two percent of
tumors were localized to the right lobe, 48% to the left.
The incidence of positive lymph nodes was 65.5%, suc-
cessful identification of SLN 93.3%, false-negative rate
25.6%, and accuracy 88.1% (Table 1). SLN biopsy was
performed using single-agent injection (methylene blue
dye) in 45 and dual-agent injection (blue dye plus radio-
active colloid) in 45 patients, respectively.
Comparison of the results using single- or dual-agent
injection is listed in Table 1. In the methylene blue
group, SLNs were identified in 39 of 45 patients (success
rate = 86.7%). Of the 39, 28 patients (71.8%) had posi-
tive cervical lymph nodes (pN+). Of the 28 with positive
cervical nodes, 7(25%) had metastases detected only in
non-positive SLNs, thus giving a false-negative rate of
38.9%, a negative predictive value of 61.1% (11/18), and
an accuracy rate of 82.1% (32/39).
In the combined technique group, SLN detection rate
was 100% (45/45), with 27 of 45 patients (60.0%) having
pN+, thus giving a false-negative rate of 14.3%, a nega-
tive predictive value of 85.7% (18/21), and an accuracy
of 93.3% (42/45) [Table 1].
No positive lymph nodes in levels I or V were identi-
fied in the 84 patients. In one patient (1.2%), the pN
was located in level II, in 6 patients (7.2%) in level III, in
8 patients (9.5%) in levels III and IV, in 8 patients (9.5%)
in level IV, and in 32 patients (38.1%) in level VI.
Table 1 Sentinel lymph node biopsy results
Number of patients (%)
methylene blue (n = 45) dual-agent (n = 45) In total (n = 84)
Overall success in identification of SLN 39 (86.7%) 45 (100%) 84 (93.3%)
Mean No. of SLN in identified (range) 2.7 (1-7) 5.4 (3-10) 4.1
No. of patients with positive SLN 21 (53.8%) 24 (53.3%) 45 (53.6%)
No. of patients with negative SLN 18 (46.2%) 21 (46.7%) 39 (46.4%)
Mean No. of lymph nodes examined 21.3 22.4 21.9
No. of patients with positive lymph nodes 28(71.8%) 27(60.0%) 55 (65.5%)
Positive lymph nodes only in NSLN 7(25.0%) 3(11.1%) 10 (20.0%)
False negative rate 38.9% 14.3% 25.6%
Accuracy 82.1% 93.3% 88.1%
Huang et al. BMC Cancer 2011, 11:386
http://www.biomedcentral.com/1471-2407/11/386
Page 3 of 7Discussion
Recent developments in SLN concept and technology
have resulted in the application of this approach to
define the first draining site or SLN to which a cancer
may have metastasized [26,27]. The underlying thesis in
solid tumor biology is that metastasis generally begins
with an orderly progression, spreading through the lym-
phatic channels to the SLN that should be reflected in
the pathological status of the subsequent lymph nodes.
Thus, the purpose of a SLN biopsy is not to improve
survival, since that has not been clearly demonstrated,
but to obtain diagnostic and prognostic information in
order to help select systemic therapy. With the possibi-
lity of systemic disease, prognosis can only be improved
by the addition of adjuvant therapy. To some extent the
degree of possibility is determined by the presence or
absence of regional nodal involvement.
The SLN technique is currently mainly used in sur-
gery for breast cancer and melanoma, although its use is
increasing in other solid tumors [3,4,6], including PTC
[7,8]. The SLN procedure has proven to be a valuable
surgical adjunct and has become the standard for the
surgical approach in the axillary staging of early-stage
breast cancer, helping avoid unnecessary dissection in
up to 75% of early-stage breast cancers [9]. Adjuvant
chemotherapy regimen and whether adjuvant radiother-
apy should or should not be given are related to the
number of ALN involved [28]. Thus, accurate assess-
ment of ALN status by ALN dissection is important, not
only for staging and prognosis, but also for guiding
treatment selection, when SLN biopsy is positive [29].
Different types of solid tumors have different patterns
and biology of lymph node metastases [30]. In most
other solid tumors, if the recurrence risk is high, more
aggressive treatment may be warranted because the
absolute reduction in the risk of recurrence is larger,
thus offsetting disadvantages related to more aggressive
treatment and improving the benefit-risk ratio. However,
in the case of PTC, the generally favorable disease biol-
ogy seems to make the extent of operation performed
less important. PTC in younger “low risk” patients have
a pattern of frequent (75%) regional nodal metastases
when nodal resections are performed, but uncommonly
(< 3%) have distant metastases, which are almost
entirely confined to the lung when they occur, and a
99% disease-free survival rate at 20 years after treatment
[31]. This unique clinical situation of very frequent
nodal metastases but excellent survival suggests the use
of SLN examination in younger patients with low-risk
PTC [32]. Presently, as to the surgical options for PTC
with gross lymph nodes involvement, there is no debate
about the need for a radical neck dissection for preven-
tion of local recurrence and systemic metastases [33].
The current controversy in the management of occult
lymph node metastases in PTC revolves around the clin-
ical contrast between the rather high incidence of
metastases in patients with clinically occult nodes (50-
80%), with a neck recurrence rate ranging from 1.4 to
30%, yet a 5-year mortality rate ranging from 0.9 to 17%
when routine nodal dissection is not performed [34,35].
Moreover, the greatest complications occurring after a
neck dissection is a 25% incidence of postoperative
shoulder dysfunction among patients who underwent a
lateral neck dissection [36], neck numbness or neuro-
pathic pain [37,38], and other postoperative sequelae
[36-39]. Further, the increasing use of preoperative
ultrasound conceivably decreases the number of clini-
cally node-negative patients [40]. Finally, life-long TSH-
suppressive doses of exogenous L-thyroxin after opera-
tion are felt to improve the prognosis of patients with
occult metastasis. For these reasons, for clinically node-
negative patients with PTC, knowledge of the presence
or absence of lymphatic metastases may be of only
interest in the staging procedure. However, if the SLN
examination is negative, it would seem worthwhile not
to have to perform further cervical node evaluation. Our
results suggest that the dual SLN procedure would best
accomplish this.
The previous studies of the efficacy of SLN biopsy in
thyroid cancer seldom segregated different subpopula-
tion in different tumor types so as not to produce more
focused finding for discrete subpopulation, which may
in reality exhibit different biological behaviors. More-
over, we hypothesized that the combination of the blue-
dye method and lymphoscintigraphy/gamma probe tech-
niques can have complementary roles and overcome
some limits (such as retrieval of SLN outside the central
compartment) to increase the possibility of identification
of SLN. Thus, our study is, to the best of our knowl-
edge, the largest comparative analysis of two techniques
of SLN biopsy for younger female patients with ipsilat-
eral low-risk PTC (T1-2N0M0) in Chinese population. In
consistence with previous reports of 21% to 82% in
patients without gross evidence of cervical lymph node
involvement [15], the incidence in this study was 71.8%
in methylene blue group, 60.0% in dual-agent group,
and 65.5% in all patients. It demonstrated the feasibility
of both procedures of SLN with identification rate of
86.7% for methylene blue only, 100% for dual-agent
technique, and 93.3% for all, with accuracy rate of 82.1%
for methylene blue only, 93.3% for dual-agent technique,
and 88.1% for all (Table 1). This was consistence with
the average rate of SLN identification with 83%
(range,65%-95%) for blue dye and 96% (range,77%-
100%) for
99 m Technetium, and accuracy rate in most
patients (range, 80%-100%) [7,8,10-20,35]. A consensus
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99 m Technetium-
labeled colloid technique yielded better detection rate of
nodal metastases (P = 0.035). Hence, for institutions
considering the application of SLN biopsy in low-risk
patients with PTC, the combining use of Technetium-99
m for SLN detection offers a potentially higher success
rate in identifying SLN. The use of blue dye technique
only for SLN detection may be less successful due to
transport of the blue dye to the parathyroid glands or
prophylactic parathyroid identification resulting the det-
rimental effect of inevitable perithyroidal tissue dissec-
tion and/or minimal thyroid mobilization on the
integrity of the lymphatic drainage before injection.
The false-negative rate (FNR) is the single most
important quality item for the SLN technique. If a nega-
tive SLN biopsy could not definitively exclude the pre-
sence of positive basin lymph nodes, it adds no further
staging information. High numbers of false-negative
SLN would render the specific technique unsuitable for
routine practice. In the present study, the FNR of the
blue dye technique of SLN is 38.9% and 14.3% for dual-
agent technique. The higher FNR of the blue dye techni-
que in my study may due to the small size of the pri-
mary tumor and low-risk of patients having more SLN
lying outside the central compartment (35.6% outside
the central compartment). The FNR of methylene blue
only was higher than it of dual-agent technique, though
the difference did not reach significance. This may be
related to the fairly small number of cases studied.
T h e r ew e r el i t t l ed a t ar e g a r d i n gt h eF N Rf o rS L N ,p r e -
vious trials reported a FNR of 11.3% for use of Techne-
tium-99 m [20] and 10.0%-17.9%for the blue dye
technique [12,13,15,16]. In early-breast cancer, the
American Society of Breast Surgeons recommends a
rate of SLN identification of 85% with a false-negative
rate of 5% or less in order to abandon axillary dissection
[29]. Hence, Regardless of the acceptable identification
rate of SLN by whichever of the both procedures was
adopted, high FNR renders considering further improve-
ment in the SLN technique for this subpopulation
before a routine application. It could not exclude the
possibility that PTC cells may more likely escape from
the first draining lymph node of and metastasize to
other lymph nodes (skip metastases) as gastric carci-
noma of 20-30% and thoracic esophagus cancer of 50-
60%[41-43], because of different patents and biology of
lymph node metastasis. More studies should investigate
the technical aspects of harvesting the SLN. Novel
methods for SLN detection are currently under investi-
gation, as are the use of MR lymphangiography and car-
bon dye labeling [44]. Furthermore, it still remains
uncertain how best to handle the SLN. The intraopera-
tive examination (frozen-section analysis) and the rout-
ing pathologic assessment of SLN can underestimate the
true incidence of metastasis [43]. False-negative SLNs
may contain tiny deposits of microscopic metastatic dis-
ease but these may not be caught in the examined histo-
logic slides. Serial sections, immunohistochemical stains
[45] and molecular marker assays (based on the reverse
transcriptase-polymerase chain reaction technique)
increase the detection rate of SLN metastases and could
identifying micrometastases [46].
Conclusion
In our study, comparing to blue dye for younger female
patients with ipsilateral low-risk PTC (T1-2N0M0), the
combined technique of SLN biopsy could help more
accurate lymph node staging and better identification of
SLN located out of the central compartment. Regardless
of the acceptable identification rate of SLN by whichever
of the both procedures was adopted, high FNR renders
the SLN technique unsuitable for routing practice; Pro-
phylactic node dissection of level VI might be consid-
ered rather than routine practice for patients who did
not had SLN biopsy, where only 38.1% of patients had
node metastasis.
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